Clinical Trials Logo

Clinical Trial Summary

The purpose of this study was to evaluate the efficacy and safety of 2 doses of Immune Globulin Intravenous (IGIV), 10% administered every 2 weeks as an intravenous (IV) infusion compared with placebo in participants with mild to moderate Alzheimer's disease (AD).


Clinical Trial Description

Study visits: Each participant will be tested at the investigational site, and if qualified, will be treated intravenously (through a vein) every two weeks for 70 weeks (approximately 18 months). The first three infusions must be done at the site, but if the infusions are well tolerated, subsequent infusions may be done by a qualified healthcare provider in the home or other suitable location. Each participant must return to the site every 3 months for evaluation of cognition as well as blood tests and scans of the brain. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00818662
Study type Interventional
Source Takeda
Contact
Status Completed
Phase Phase 3
Start date December 19, 2008
Completion date December 10, 2012

See also
  Status Clinical Trial Phase
Terminated NCT02245737 - An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Phase 2/Phase 3
Completed NCT02360527 - Retinal Neurodegeneration in Type 2 Diabetes as Biomarker for Alzheimer´s Disease N/A
Completed NCT01225809 - AD01 Follow up Extension Visit N/A
Terminated NCT01117948 - Efficacy and Safety of Lornoxicam in Patients With Mild to Moderate Probable Alzheimer´s Disease. Phase 2
Terminated NCT01736579 - Long-Term Study of IGIV, 10% in Alzheimer´s Disease Phase 3
Completed NCT02501876 - Type 2 Diabetes Mellitus as Catalyst for Alzheimer's Disease N/A
Active, not recruiting NCT01695889 - Is There a Relationship Between Previous Exposure to General Anesthesia and the Development of Alzheimer´s Disease? N/A
Completed NCT00608946 - Treatment With Copper in Patients With Mild Alzheimer´s Dementia Phase 2
Terminated NCT02008513 - Follow-up Study to Assess Safety and Clinical Activity of Continued AFFITOPE® AD02 Vaccinations of Patients Who Participated in AFF006 Phase 2
Completed NCT02224326 - Vagus Somatosensory Evoked Potentials and Near-infrared Spectroscopy in the Early Diagnosis of Dementia
Terminated NCT01125683 - To Evaluate Effects of AZD1446, Placebo and Donepezil in Patients With Alzheimer's Disease Phase 2
Terminated NCT01357629 - Observational Follow-up Extension Study of AFF002 and AFF004A in Patients With Alzheimer's Disease N/A
Terminated NCT01524887 - Phase 3 IGIV, 10% in Alzheimer´s Disease Phase 3
Completed NCT00692705 - Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid Phase 1
Active, not recruiting NCT02623764 - EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors
Completed NCT00948259 - Safety Study of a Glycogen Synthase Kinase 3 (GSK3) Inhibitor in Patients With Alzheimer´s Disease Phase 1/Phase 2